Current prostate cancer diagnostics are inadequate - they lack sensitivity and prognostic value. Cellanyx is offering a predictive, sensitive, and cost effective solution to inform physicians at the radical prostatectomy decision point. Cellanyx's technology will improve the diagnostic process, increasing patient quality of life - significantly reducing health care costs.
Leveraging lab-on-a-chip technology & novel biomarkers, Cellanyx is developing a prognostic central lab service for prostate cancer.
2012 Silver Winner